An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions.
J Infect Dis
; 220(4): 557-566, 2019 07 19.
Article
in En
| MEDLINE
| ID: mdl-30957170
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Quinoxalines
/
Benzofurans
/
Hepacivirus
/
Hepatitis C, Chronic
/
Imidazoles
/
Liver Cirrhosis
Type of study:
Clinical_trials
/
Guideline
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Humans
/
Middle aged
Language:
En
Journal:
J Infect Dis
Year:
2019
Type:
Article